Our research revealed a correlation between elevated RAC3 levels and diminished sensitivity to specific therapeutic agents, such as mitoxantrone, a chemotherapeutic agent for bladder cancer, as well as SB505124 and VE-822. The gene discussed is RAC3; the disease is urinary bladder cancer.